Protocols

Biogen recruits Roche vet Ghosh as head of research, early development; Cell Medica raises £60 million; Aerpio bags $40M raise

Anirvan Ghosh

→ Biogen has recruited Roche vet Anirvan Ghosh as its new SVP of research and early development. He is joining Biogen from E-Scape Bio, where he worked on Alzheimer’s and neurosciences work. And at Roche he had been global head of neuroscience discovery and biomarkers. “Biogen has been a pioneer in bringing breakthrough medicines to patients with multiple sclerosis and spinal muscular atrophy, as well as finding new approaches for Alzheimer’s disease, Parkinson’s disease, and ALS – conditions that represent some of the hardest challenges in medicine,” said Dr. Ghosh.

→ The UK’s Cell Medica bagged a £60 million Series C with participation from Touchstone Innovations, Invesco Perpetual, and Woodford Investment Management. The biotech plans to use the money for its cell-based immunotherapy products. Cell Medica’s lead product, baltaleucel-T (CMD-003), is in the CITADEL Phase 2 clinical trial for the treatment of patients with advanced lymphomas associated with the Epstein-Barr virus.

→ Aerpio Pharmaceuticals executed a reverse merger and raised $40 million from Novartis Venture Fund, OrbiMed, Satter Investment Management, Kearny Venture Partners, Venture Investors, LLC., and Triathlon Medical Ventures. New institutional investors, Montrose Capital Partners and Ally-Bridge, also participated in the offering. The biotech is a launching a 150 patient, Phase 2b trial of once- and twice-daily dosing of AKB-9778 for 12 months to evaluate the safety and efficacy of the drug in patients with moderate to severe DR without diabetic macular edema.


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy